OncoSec Medical to Present at LD Micro 4th Invitational
June 03 2014 - 5:02AM
Business Wire
Live Webcast Available for First Post-ASCO
Presentation
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its
ImmunoPulse DNA-based intratumoral cancer immunotherapy, will
present at the LD Micro 4th Invitational, taking place Wednesday,
June 4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
This presentation will be the first of its kind to include new
positive interim data from the company’s Phase 2 melanoma study,
which was recently exhibited at the 2014 ASCO Annual Meeting.
The company’s presentation by Robert Pierce, M.D., OncoSec Chief
Medical Officer, is scheduled to begin at 1:00 p.m. PDT and will be
available via live webcast. To access the webcast, please use the
following link: http://wsw.com/webcast/ldmicro6/oncs.
About LD Micro 4th Invitational
LD MICRO is an investment newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since 2002,
the firm has published an annual list of recommended stocks, as
well as comprehensive reports on select companies throughout the
year. The 4th Invitational will feature company presentations and
facilitate 1-on-1 meetings between business leaders and investors,
as part of LD Micro’s ultimate goal of bringing out the finest
ideas in micro-cap and showcasing them to a tight-knit and loyal
investor base. For more information, please visit:
http://www.ldmicro.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse DNA-based intratumoral cancer immunotherapy.
OncoSec Medical's core technology leverages a proprietary
electroporation platform to enhance the local delivery
and uptake of IL-12 and other DNA-based immune-modulating agents.
Clinical studies of ImmunoPulse have demonstrated an acceptable
safety profile and preliminary evidence of anti-tumor activity in
the treatment of various skin cancers, as well as the potential for
a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
respectively
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination-based approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2024 to May 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024